Background: Varenicline, which is a selective partial agonist of the alpha4-beta2 nicotinic acetylcholine receptor, is used for the smoking cessation pharmacotherapy. Cardiovascular adverse effects have been reported after varenicline usage in patients who stop smoking. We investigated the effect of varenicline usage on ventricular repolarization after smoking cessation.
| INTRODUC TI ON
Cigarette smoking is a well-accepted cardiovascular disease risk factor worldwide. Unfortunately, smoking-related deaths are expected to increase from 6 million in 2010 to 10 million by 2040 (Jha & Peto, 2014) . Smoking addicts who stop smoking can prevent more adverse cardiovascular events than any other preventive strategies such as aspirin, physical exercise, or diet (Gohlke, 2013) . Varenicline has been available as a pharmacotherapy for smoking cessation since Liaisons, and Staff, 2008) . Varenicline is selective partial agonist of the alpha4-beta2 nicotinic acetylcholine receptor (Cahill, Stead, & Lancaster, 2012) . Among patients not able to quit smoking, use of varenicline for 24 weeks significantly increased smoking cessation (Ebbert et al., 2015) . Following the important success of the varenicline, the adverse effects of the varenicline should be discussed in detail.
Electrocardiography (ECG) is the most useful noninvasive clinical tool in the cardiology clinical practice. Many measurements in ECG were defined to predict the risk of ventricular arrhythmias. The QT interval, corrected QT interval (QTc), Tpeak-Tend (Tp-e) , and Tp-e/ QTc ratio are the most popular repolarization parameters due to their predictive role for the ventricular arrhythmias (Dural & Mert, 2017; Zehir et al., 2015) . Since varenicline is a partial agonist of alpha4-beta2 nicotinic acetylcholine receptor, it could also affect autonomic nervous system by binding alpha3-beta4 and alpha7 acetylcholine receptors (Ari et al., 2015) . Hence, after the modulation of the equilibrium between sympathetic and parasympathetic system, the repolarization of the heart muscle cells may be changed. The change in the QTc interval, Tp-e and Tp-e/QT ratio after a certain time of varenicline administration could help us to understand the pro-arrhythmic effect of varenicline. The patients who want to stop smoking often have a concomitant ischemic heart disease; therefore, arrhythmic effects of varenicline gain importance. The electrocardiographic effects of multiple doses of varenicline usage have not been reported yet. The aim of our study was to assess the effect of varenicline usage on the ventricular repolarization parameters after smoking cessation.
| MATERIAL S AND ME THODS

| Patient and study design
Our prospective cohort study was designed to evaluate the Tp-e interval, QTc, and Tp-e/QTc ratio during smoking and after smoking cessation with varenicline. Between January 2018 and April 2018, 258 smokers of all ages were prospectively enrolled in the study. Patients were admitted to Selçuk University Family Medicine Clinic. Patients were included if they accepted to use varenicline in the described form. Exclusion criteria were re-smoking, having coronary artery disease, congestive heart failure, significant aortic or mitral valve disease, atrial fibrillation, bundle branch block or evidence of any other intraventricular conduction abnormalities, ECGs without a clearly computable QT segment, diabetes mellitus, thyroid disorders, and taking any chronotropic medication such as beta-blockers. Among 258 patients, those with re-smoking (n = 16), those with atrial fibrillation (n = 6), those with bundle branch block (n = 2), those with coronary artery disease (n = 8), those with extensive negative T waves on ECGs (n = 6), and those with diabetes mellitus (n = 6) were excluded. Therefore, 214 patients fulfilling the inclusion criteria and 50 sex-,body mass index (BMI)-,and age-matched ex-smoker patients who quit smoking without varenicline usage were finally enrolled in the study. A standard 12-lead ECG (Schiller, Cardiovit AT-10 plus) (filter 150 Hz, 25 mm/s, 10 mm/mV) was obtained from all patients prior to varenicline utilization and after 2 months of varenicline utilization.
ECGs were scanned at 300 DPI, and images were amplified 10×. The QT interval was measured manually as the duration between the beginning of the Q wave and the end of the T wave using a caliper on an individual basis. The PQ interval was measured manually as the duration between the beginning of the P wave and the beginning of the Q wave using a caliper on an individual basis. The QTc interval was calculated using the Fridericia's and Framingham's formulas (Fridericia, 1920; Goldenberg, Moss, & Zareba, 2006; Sagie, Larson, Goldberg, Bengtson, & Levy, 1992) . The Tp-e interval was calculated from the peak of the T wave to the end of the T wave. The end of the T wave was defined as the intersection of the tangent of the downslope of the T wave and isoelectric line. In the presence of the U wave, the nadir point between the T and U waves was measured.
Tp-e/QTc ratio was also measured.
| Follow-up
All of our patients started varenicline dosage of 0.5 mg once daily for three days. The dose was increased to 0.5 mg twice daily between days 4-7. After day 7, patients were asked to use maintenance dose of 1 mg twice daily. Patients were evaluated again after two months of varenicline usage. The venous blood samples and ECGs were also evaluated.
| Statistical analysis
Data were analyzed with Statistical Package for Social Sciences (SPSS) version 20.0 for Windows (IBM, Armonk, NY, USA). Normality of distribution will be assessed using Kolmogorov-Smirnov test.
Continuous variables will be defined as the mean ± standard deviation. Categorical variables will be presented as number and percentages. Differences in the median values between groups were analyzed using Mann-Whitney U test. Categorical variables were analyzed by chi-square test or Fisher's exact test. For repeated measurements, paired sample t test and Wilcoxon signed-rank tests were used to evaluate the significance of the difference in parameters with normal and skewed distribution, respectively. Spearman correlation analysis was used for the correlation between packet/ year and change in Tp-e and QTc intervals. Statistical significance was defined as a p value <0.05.
| RE SULTS
Two hundred fourteen (71% male) patients admitted to the smoking cessation clinic and prescribed varenicline were evaluated in our study. Patients were analyzed according to their change in the ventricular repolarization features. Mean age of varenicline prescribed patients was 38.9 ± 11.5 years. The laboratory and ECG data of the patients during smoking and after smoking cessation with varenicline were compared in Table 1 . There was no significant difference in hemoglobin level, TSH, free T3, free T4, sodium, potassium, calcium and magnesium levels before and after smoking cessation with varenicline. Considering electrocardiographic parameters, the heart rate and Tp-e interval were similar before and after smoking cessation with varenicline. After calculated according to Fridericia's and Framingham's formulas, QTc intervals were significantly increased after varenicline usage (402.9 ± 24.5 ms vs. 409.1 ± 25.0 ms p < 0.001 and 376.5 ± 15.2 ms, vs. 380.6 ± 13.5 ms; p < 0.001, respectively).
The laboratory and ECG data of the control group and varenicline prescribed group were presented in Table 2 . The two groups were similar in terms of age, gender, body mass index, laboratory values, and heart rate. The mean Tp-e interval was significantly prolonged in the varenicline prescribed group compared with the control group (78.2 ± 6.9 vs. 69.5 ± 4.0; p < 0.001).
QTc Fridericia (409.1 ± 25.0 vs. 388.3 ± 28.6; p < 0.001) and QTc Framingham (380.6 ± 13.5 vs. 365.0 ± 16.2; p < 0.001) were significantly higher in the varenicline prescribed group than in the control group. 
| D ISCUSS I ON
Our study is a pilot study indicating varenicline usage to prolong QTc interval after smoking cessation compared to the same patients' smoking status independent from QTc calculation model. Varenicline usage was also found to prolong QTc and Tp-e interval when compared to sex-,body mass index (BMI)-,and age-matched ex-smoker patients who quit smoking without varenicline. Also, there was a negative correlation between smoking packet/year and the change in Tp-e interval and QTc after varenicline usage.
Varenicline has several adverse effects including basically cardiovascular and neuropsychiatric systems. (Singh, Loke, Spangler, & Furberg, 2011) . Despite the adverse effects, the US Food and Drug Administration reported a safety communication noting a lower incidence of cardiovascular mortality and all-cause mortality in varenicline group when compared to placebo group (Thomas, Martin, Knipe, Higgins, & Gunnell, 2015) . Nevertheless, several cardiovascu- (Niedermaier et al., 1993) . The another possible mechanism is the continuation of smoking and dual stimulus of catecholamine release may cause cardiac dysrhythmias.
Thus, in our study, we excluded the re-smoker patients in order to TA B L E 1 Laboratory and electrocardiography findings of the varenicline prescribed patients isolate the effect of varenicline on the ventricular repolarization parameters. The QTc interval, Tp-e, and Tp-e/QTc ratio were used in the study to represent the cardiac dysrhythmias potential.
The effect of varenicline administration should be divided into two as acute or chronic usage. QTc, Tp-e, and Tp-e/QTc are prolonged after acute varenicline usage in smokers (Ari et al., 2015) .
In the non-smoker group, there is no significant change in these parameters after varenicline usage (Ari et al., 2015) . Faessel et al. (2006) also have reported acute varenicline exposure to have no effect on QTc or electrocardiography morphology. On the other hand, findings from an animal study have shown that QT interval is prolonged in the chronic varenicline usage (Selçuk et al., 2015) .
Similarly, in our study, it was presented that QTc was prolonged in chronic varenicline usage compared to QTc in smoking. Moreover, QTc and Tp-e intervals were longer when compared to ex-smoker patients who quit smoking without varenicline. QTc, Tp-e, and Tp-e/ QTc are demonstrated to increase in smokers (Taşolar et al., 2014) .
In addition, the increase in QTc, Tp-e, and Tp-e/QTc were correlated to the smoking packet/year (Taşolar et al., 2014) . Interestingly, in our study, the change in QTc and Tp-e intervals were negatively correlated with the smoking packet/year. The change in QTc and
Tp-e was less in patients who smoked more. This correlation was compatible with the effect of smoking on QTc, Tp-e, and Tp-e/QTc.
Electrolyte imbalances are also defined as a predisposing factor for cardiac dysrhythmias (Hayıroğlu, Keskin, & Kozan, 2017; Vandael, Vandenberk, Vandenberghe, Willems, & Foulon, 2017) . In our study population, the electrolytes and other predisposing arrhythmic factors were similar between the study groups. Therefore, we had an accurate opportunity to evaluate the effects of varenicline usage on the ventricular repolarization parameters. TA B L E 2 Baseline characteristics, laboratory and electrocardiography findings F I G U R E 1 Mean Tp-e, QTc intervals, and Tp-e/QTc ratios were higher in varenicline prescribed patients than in control patients
| Study limitations
The current study has several limitations. Firstly, this was a single-center and observational study; however, it was conducted in a high volume smoking cessation clinic and all consecutive patients who met the criteria were included, thus limiting selection bias. Secondly, Tp-e interval has been accepted as a measure of transmural dispersion of repolarization and was associated with ventricular arrhythmias but this marker did not prove varenicline as a pro-arrhythmic drug. Re-smoker patients were excluded in order to evaluate the varenicline usage on ventricular repolarization parameters. Thirdly, other factors such as alteration in autonomic tone associated with smoking cessation could have caused the change in ventricular repolarization parameters in our study population. Therefore, randomized controlled trials are warranted to make precise inferences.
| CON CLUS ION
Our pilot study presented that QTc was increased after varenicline usage. The change in Tp-e and QTc were negatively correlated with the smoking packet/year. Varenicline may have a role to predispose cardiac dysrhythmias after utilization in smoking cessation. Further investigations on independent multicentre cohorts should be performed in order to validate our findings.
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